Vinorelbine (Navelbine ) - Indications, Dosage, Side effects

Vinorelbine (Navelbine ) is a semisynthetic vinca alkaloid which binds to tubulin and inhibits microtubule formation.

It is used as a first-line treatment (in combination with cisplatin) of locally advanced or metastatic non-small cell lung cancer (NSCLC)

It is also the single-agent treatment of metastatic NSCLC.

  • Off Label Usage of Vinorelbine in Adults:

    • Metastatic Breast cancer

    • Persistent or recurrent cervical cancer

    • Relapsed or refractory Hodgkin lymphoma,

    • Malignant pleural mesothelioma

    • Relapsed Ovarian cancer

    • Recurrent Salivary gland cancer

    • Refractory Small cell lung cancer

    • Advanced soft tissue sarcoma

Vinorelbine Dose in Adults

Off label Dosage in the treatment of metastatic Breast cancer:

  • 25 mg/m² intravenous once weekly (as a single agent) until disease progression or unacceptable toxicity
  • An alternative is 30 mg/m² once weekly (as a single agent)
  • After 13 weeks, Dosing interval can be changed to every 14 days (for patient convenience)
  • It is continued until either the disease progress or the patient develops unacceptable toxicity.
  • Another option is to give 25 mg/m² every 7 days (in combination with trastuzumab) until disease progression or unacceptable toxicity
  • Another alternative dosage is 30 or 35 mg/m² days 1 and 8 every 21 days (in combination with trastuzumab) until disease progression or unacceptable toxicity.

Off label dosage in the treatment of Cervical cancer:

  • 30 mg/m² intravenous on days 1 and 8 of a 2-week treatment cycle

Off label dosage in the treatment of relapsed or refractory Hodgkin lymphoma:

  • GVD regimen:
    • It is given 15 mg/m² (post-transplant patients)
    • It can also be given as 20 mg/m² (transplant-naïve patients) on days 1 and 8 of a 21-day cycle (in combination with gemcitabine and doxorubicin liposomal) for 2 to 6 cycles
  • IGEV regimen:
    • It is given 20 mg/m² on day 1 of a 2-week cycle (in combination with ifosfamide, mesna, gemcitabine, and prednisolone) for 4 cycles

Off label dosage in the treatment of malignant pleural mesothelioma :

  • It is given 30 mg/m² (maximum dose: 60 mg) every 7 days per 6-week treatment cycle
  • It is continued until disease progression
  • It is also be given 30 mg/m² (maximum dose: 60 mg) every 7 days for 6 weeks, off 2 weeks, then repeat the cycle

Dosage in the treatment of Non-small cell lung cancer (NSCLC):

Metastatic (single-agent therapy):

  • It is given 30 mg/m² once a week

Locally advanced or metastatic (in combination with cisplatin):

  • It is given 25 mg/m² on days 1, 8, 15, and 22 of a 28-day cycle or 30 mg/m² once a week

Advanced NSCLC (off-label dosing):

  • It is given 25 to 30 mg/m² days 1, 8, and 15 every 28 days (in combination with gemcitabine) for 6 cycles or until disease progression or unacceptable toxicity occurs

Off label dosage in the treatment of relapsed Ovarian cancer:

  • It is given  25 mg/m² intravenous every 7 days
  • It is also be given  30 mg/m² days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity occurs

Off label dosage in the treatment of recurrent Salivary gland cancer:

  • It is given 25 mg/m² intravenous on days 1 and 8 of a 21-day cycle (in combination with cisplatin) for a minimum of 3 cycles and for up to 6 cycles

Off label dosage in the treatment of refractory Small cell lung cancer:

  • It is given 25 or 30 mg/m² intravenous every 7 days until disease progression or unacceptable toxicity.

Off label dosage in the treatment of advanced Soft tissue sarcoma:

  • It is given 25 mg/m² intravenous on days 1 and 8 of a 21-day treatment cycle (in combination with gemcitabine) until disease progression or unacceptable toxicity occurs

Vinorelbine Dose in Childrens

Dose in the treatment of refractory or recurrent Hodgkin’s lymphoma: 

  • Children ≥10 years and Adolescents:
    • It is given  25 mg/m² IV once weekly on days 1 and 8 of a 3-week cycle in combination with gemcitabine

Dose in the treatment of refractory, or recurrent acute Leukemias (ALL, AML):

  • Infants:
    • It is given as 67 mg/kg once weekly on days 0, 7, 14 of a 2-week cycle in combination with topotecan, clofarabine, and thiotepa (TVTC regimen)
  • Children and Adolescents:
    • It is given  20 mg/m² once weekly on days 0, 7, and 14 of a 2-week cycle in combination with topotecan, clofarabine, and thiotepa (TVTC regimen)

Dose in the treatment of refractory or recurrent solid tumors:

  • Children and Adolescents:
    • Monotherapy:
      • It is given 30 mg/m once weekly for weeks 1-6 of an 8-week cycle for 10 courses
      • It may be reduced  to 27 mg/m for Grade 3 or 4 hematologic toxicity in patients who show an objective response or who have had treatment delay beyond 63 days (week 9) from the previous course
    • Combination therapy:
      • It is given  25 mg/m² once weekly for 3 weeks on days 1, 8, and 15 of each 4-week cycle in combination with cyclophosphamide
    • Dosing adjustment for toxicity:
      • The presented dosing adjustments are based on the dosage given in adult patients. Refer to a specific protocol for management in pediatric patients if available.
  • In patients with hematologic toxicity and hepatic impairment at the same time, give the lower of the doses determined from the adjustment recommendations.
    • Granulocyte counts should be more than 1000 cells/mm³ before the administration of vinorelbine.
    • Adjustments in the dose should be made on granulocyte counts obtained on the day of treatment as follows:
      • Granulocytes more than 1500 cells/mm³ on day of treatment:
        • Give 100% of starting dose
      • Granulocytes 1000-1499 cells/mm³ on day of treatment:
        • Give 50% of starting dose
      • Granulocytes <1000 cells/mm on day of treatment:
        • Do not give. Repeat granulocyte count in 1 week; if 3 consecutive doses are not given because granulocyte count is <1000 cells/mm³, stop vinorelbine.
      • For patients who, during treatment, have experienced fever and/or sepsis while granulocytopenia or had 2 consecutive weekly dose not given due to granulocytopenia, subsequent doses of vinorelbine should be:
        • 75% of the starting dose for granulocytes more than 1500 cells/mm³
        • 50% of the starting dose for granulocytes 1000-1499 cells/mm³
      • Neurotoxicity ≥grade 2:
        • Stop treatment
      • Severe adverse events:
        • Reduce dose or stop treatment

Vinorelbine pregnancy Risk Factor: D

  • Vinorelbine may cause harm to the fetus if given to pregnant women.
  • Before treatment can be initiated for females with reproductive potential, it is important to verify their pregnancy status.
  • For effective contraception, pregnant women of reproductive potential must be advised that they are able to use it during vinorelbine treatment as well as for six months afterward.
  • Effective contraception should be used by males who have female partners with reproductive potential during treatment and for three months after the last vinorelbine dosage.
  • Vinorelbine may damage the spermatozoa, which can lead to decreased fertility in male patients.

Vinorelbine can be used during lactation

  • Breastfeeding is not recommended during treatment or for the first 9 days following the last vinorelbine dose.

Vinorelbine (Navelbine) dose in Renal disease: 

There are no dosage adjustments given in the manufacturer's labeling.

Hemodialysis:

  • Initially reduce dose to 20 mg/m² once a week
  • Then administer either after dialysis (on dialysis days) or on nondialysis days

Vinorelbine (Navelbine) dose in Liver disease: 

  • Patients with concomitant hematologic toxicities and hepatic impairment should be given the lowest dose as per the adjustment recommendations.
  • Patients with hepatic impairment should be cautious.
  • Patients who become hyperbilirubinmic after treatment with vinorelbine should adjust their dose for total bilirubin, as follows:
    • Serum bilirubin lower than 2 mg/dL
      • Take 100% of the dose
    • Serum bilirubin, 2.1 to 3.0 mg/dL
      • Half the dose should be given
    • More than 3 mg/dL serum bilirubin:
      • 25% of the dose should be given
    • Patients with advanced liver metastases (more that 75% of the liver volume) (breast Cancer):
      • Half the dose should be given

Common Side Effects of Vinorelbine Include:

  • Central Nervous System:
    • Neurotoxicity
    • Peripheral Neuropathy
  • Dermatologic:
    • Alopecia
  • Gastrointestinal:
    • Nausea
    • Vomiting
    • Constipation
    • Diarrhea
  • Hematologic & Oncologic:
    • Neutropenia
    • Leukopenia
    • Anemia
  • Hepatic:
    • Increased Serum Aspartate Aminotransferase
  • Local:
    • Injection Site Reaction
    • Pain At Injection Site
  • Neuromuscular & Skeletal:
    • Asthenia
  • Renal:
    • Increased Serum Creatinine

Less Common Side Effects of Vinorelbine Include:

  • Cardiovascular:
    • Localized phlebitis
    • chest pain
  • Central nervous system:
    • Neuropathy
  • Hematologic & oncologic:
    • Febrile neutropenia
    • thrombocytopenia
  • Hepatic:
    • Increased serum bilirubin
  • Infection:
    • Sepsis
  • Otic:
    • Ototoxicity
  • Respiratory:
    • Dyspnea

Frequency not defined:

  • Gastrointestinal:
    • Intestinal Necrosis
    • Intestinal Obstruction
    • Intestinal Perforation
    • Paralytic Ileus
  • Hematologic & Oncologic:
    • Bone Marrow Depression
  • Hepatic:
    • Hepatotoxicity
  • Respiratory:
    • Interstitial Pulmonary Disease
    • Pulmonary Toxicity (Including Acute Respiratory Distress Syndrome
    • Interstitial Pneumonitis
    • Severe Acute Bronchospasm)

Contraindication to Vinorelbine Include:

  • The manufacturer's labeling does not list any contraindications.

Warnings and precautions

  • Suppression of bone marrow: [US Boxed Warning]
    • Septic shock, death, or severe myelosuppression can result in serious infections, hospitalizations, and even death.
    • It could require treatment interruption, dose reduction and/or discontinuation.
    • Vinorelbine can cause anemia, neutropenia, and thrombocytopenia. It can be used alone or in combination with other chemotherapy.
    • Neutropenia, which is the most severe dose-limiting toxicity (grades 3 and 4 neutropenia have often been observed).
    • Neutropenia can lead to hospitalization for fever and/or sepsis.
    • The neutrophil nadir is reached between 7-10 days after administration. Recovery occurs within 7-14 days.
    • Before each dose, monitor your complete blood count.
    • Based on blood counts taken on the day of therapy, adjust the dose.
    • If ANC is less than 1000/mm, do not administer.
  • Extravasation
    • Before infusion, use Vesicant to ensure the proper position of the needle or catheter.
    • Avoid excessive use.
    • Extravasation can lead to tissue necrosis or thrombophlebitis.
  • Gastrointestinal toxicities:
    • Vinorelbine may cause severe and fatal paralytic and fatal ileus, necrosis and intestinal obstruction. Perforation can also occur.
    • To reduce constipation, bowel obstruction, and paralytic ileus, you can start a prophylactic stool regimen.
    • Oral vinorelbine has moderate antiemetic properties
    • To prevent nausea/vomiting, antiemetics can be used
    • IV vinorelbine is very low in emetic potential
  • Hepatotoxicity
    • Patients receiving vinorelbine can experience a drug-induced increase in transaminases or bilirubin elevations. This could be either as a single-agent treatment or in combination chemotherapy.
    • Before treatment begins, monitor liver function and continue to do so throughout treatment.
    • Patients with total bilirubin levels >2 times the ULN should be advised to reduce their doses.
    • Vinorelbine elimination occurs predominantly through the liver; patients with impaired hepatic function should be cautious and dose reductions advised.
  • Neuropathy
    • Patients who receive vinorelbine may develop motor and sensory neuropathies.
    • Monitor for signs and symptoms of muscle weakness or neuropathy. This includes paresthesia, hyperesthesia, hyporeflexia, and hyperesthesia.
    • Vinorelbine should be stopped if you have >= grade 2 neuropathy.
  • Toxicity in the lungs:
    • Vinorelbine can cause pulmonary toxicity. This includes severe acute bronchospasm and interstitial pneumonitis.
    • The median time it took for interstitial pneumonia and ARDS to develop was 7 days. This ranged from 3 to 8 days.
    • Patients who have unexplained dyspnea, or any evidence of pulmonary toxicities should be treated with vinorelbine.
    • Stop vinorelbine permanently if you have been diagnosed with interstitial pneumonitis (ARDS) or confirmed interstitial pneumonia.

Monitor:

  • CBC with differential and platelet count (before each dose, and after treatment),
  • Liver function tests;
  • Confirm pregnancy status in females of reproductive potential prior to treatment initiation.
  • Monitor for new-onset pulmonary symptoms (or worsening from baseline);
  • monitor for new or worsening symptoms neuropathy.
  • monitor for signs and symptoms of constipation and ileus
  • monitor infusion site regularly

How to administer Vinorelbine?

For intravenous use only. It may be fatal if given by other routes.

  • Give over 6 - 10 minutes
  • Follow the infusion with at least 75 to 125 mL of a compatible solution to lessen the incidence of phlebitis and inflammation.
  • It is a vesicant, ensure proper needle or catheter position before administration.
  • Avoid extravasation.

Extravasation management:

  • If extravasation happens, stop infusion immediately and disconnect (leave cannula/needle in place)
  • Aspirate the extravasated solution gently
  • Do NOT flush the line
  • Start hyaluronidase antidote
  • remove needle/cannula
  • apply dry warm compresses for 20 minutes 4 times a day for 1 - 2 days
  • elevation of extremity should be done
  • The remaining portion of the vinorelbine dose should be given through a separate vein.

Hyaluronidase:

  • If needle/cannula still in place, give 1 to 6 mL hyaluronidase (150 units/mL) into the existing IV line
  • the usual dose is 1 mL hyaluronidase for each 1 mL of the extravasated drug.
  • If needle/cannula is removed then inject 1 to 6 mL (150 units/mL) subcutaneously in a clockwise manner using 1 mL for each 1 mL of drug extravasated
  • It can also be administered 1 mL (150 units/mL) as 5 separate 0.2 mL injections (using a 25-gauge needle) subcutaneously into the extravasation site

Mechanism of action of Vinorelbine:

  • It is semisynthetic vinca, an alkaloid that binds to tubulin.
  • It stops the formation of the mitotic spindle and arrests the cell in metaphase
  • Vinorelbine has a specific use for the M- and S phases.
  • Vinorelbine may also cause interference with protein synthesis and nucleic acids by blocking glutamic acid usage.
  • Distribution: It binds extensively to human platelets and lymphocytes (80% to 91%)

Protein binding:

  • 80% - 91%

Metabolism:

  • Extensively via hepatic, via CYP3A4, to two metabolites, deacetylvinorelbine (active) and vinorelbine N-oxide

Half-life elimination: Triphasic:

  • Children and Adolescents 2 - 17 years of age: 16.5 ± 9.7 hours
  • Adults: Terminal: ~28 to 44 hours

Excretion:

  • Fecal route (~46%)
  • urine (~18%, 10% to 12% as unchanged drug)

International Brands of Vinorelbine:

  • Eberelbin
  • Filcrin
  • Navelbin
  • Navelbine
  • Navildez
  • Viessia
  • Vilne
  • Vinbine
  • Vinelbine
  • Vinorel
  • Vinorelsin
  • Vinorgen
  • Vinotec
  • Vinotel
  • Zinavin

Vinorelbine Brands in Pakistan:

Vinorelbine (Tartrate) [Inj 10 Mg/Ml]

Eberelbin Bio Pharma
Navelbine Atco Laboratories Limited
Vinelbine Atco Laboratories Limited
Vinkebir Oncogene Pharmaceuticals Karachi

Vinorelbine (Tartrate) [Inj 50 Mg/Ml]

Eberelbin Bio Pharma
Navelbine Atco Laboratories Limited
Vinelbine Atco Laboratories Limited
Vinkebir Oncogene Pharmaceuticals Karachi

Comments

NO Comments Found